AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8737615 — intervention group
Group type: COMPARATOR
Intervention: Oral estradiol
Number of subjects: 25
Study 1332634 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen-norethindrone
Number of subjects: 74
Study 1332634 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen-norethindrone + Cholecalciferol
Number of subjects: 74
Study 1332634 — intervention group
Group type: COMPARATOR
Intervention: Cholecalciferol
Number of subjects: 74
Study 1332634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 3968608 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased fluid intake (mean 59%, range 26% to 140%)
Number of subjects: 26
Study 3968608 — intervention group
Group type: COMPARATOR
Intervention: Baseline fluid intake
Number of subjects: 26
Study 31379195 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine disintegrating tablets at a dose of 5 mg
Number of subjects: 0
Study 28844333 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee targeted exercises combined with foot targeted exercises and foot orthoses
Number of subjects: 40
Study 28844333 — intervention group
Group type: COMPARATOR
Intervention: Knee targeted exercises
Number of subjects: 40
Study 26815638 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month participatory, team-based educational intervention consisting of 12 biweekly learning sessions
Number of subjects: 29
Study 26815638 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month participatory, team-based educational intervention
Number of subjects: 29
Study 24604216 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-point Dixon-based MRI (2pt-MRIDIXON)
Number of subjects: 50
Study 24604216 — intervention group
Group type: COMPARATOR
Intervention: Visual assessment of muscle fat content (MFC)
Number of subjects: 50
Study 21835468 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TCES
Number of subjects: 36
Study 21835468 — intervention group
Group type: COMPARATOR
Intervention: Control (sham TCES)
Number of subjects: 36
Study 20670088 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injections of different allergens for 24 months
Number of subjects: 36
Study 20670088 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injections of different allergens for 18 months
Number of subjects: 36
Study 16938099 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization appliance
Number of subjects: 60
Study 16938099 — intervention group
Group type: COMPARATOR
Intervention: Control appliance
Number of subjects: 60
Study 12956739 — intervention group
Group type: EXPERIMENTAL
Intervention: MPL-adjuvanted grass pollen allergy vaccine
Number of subjects: 0
Study 12956739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10849983 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm-rest immobilization
Number of subjects: 30
Study 10849983 — intervention group
Group type: COMPARATOR
Intervention: Vacuum bag immobilization
Number of subjects: 30
Study 9354313 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-044 25 mg
Number of subjects: 18
Study 9354313 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-044 50 mg
Number of subjects: 18
Study 9354313 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-044 100 mg
Number of subjects: 18
Study 9354313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 1342112 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine 50 mg/Kg
Number of subjects: 124
Study 1342112 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine 25 mg/Kg
Number of subjects: 124
Study 3007066 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation
Number of subjects: 15
Study 3007066 — intervention group
Group type: COMPARATOR
Intervention: Total‐body radiation (3.6 Gy)
Number of subjects: 15
Study 3007066 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin A administration
Number of subjects: 15
Study 3007066 — intervention group
Group type: COMPARATOR
Intervention: Buffy‐coat transfusion
Number of subjects: 15
Study 3007066 — intervention group
Group type: COMPARATOR
Intervention: Antithymocyte globulin
Number of subjects: 15
Study 29577826 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain-relieved nursing home residents
Number of subjects: 239
Study 29577826 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of falling
Number of subjects: 239
Study 29577826 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective pain treatment
Number of subjects: 239
Study 30237219 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate treatment
Number of subjects: 20
Study 30237219 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 26845317 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mW/cm2 for 30 minutes
Number of subjects: 25
Study 26845317 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 mW/cm2 for 10 minutes
Number of subjects: 25
Study 26845317 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 mW/cm2 for 5 minutes
Number of subjects: 25
Study 26845317 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mW/cm2 for 3 minutes
Number of subjects: 25
Study 26845317 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 mW/cm2 for 2 minutes
Number of subjects: 25
Study 26845317 — intervention group
Group type: COMPARATOR
Intervention: Control for group-A
Number of subjects: 25
Study 26845317 — intervention group
Group type: COMPARATOR
Intervention: Control for group-B
Number of subjects: 25
Study 26845317 — intervention group
Group type: COMPARATOR
Intervention: Control for group-C
Number of subjects: 25
Study 26845317 — intervention group
Group type: COMPARATOR
Intervention: Control for group-D
Number of subjects: 25
Study 26845317 — intervention group
Group type: COMPARATOR
Intervention: Control for group-E
Number of subjects: 25
Study 25178809 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 1400
Study 25178809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1400
Study 25178809 — intervention group
Group type: EXPERIMENTAL
Intervention: M. indicus pranii
Number of subjects: 1400
Study 22621300 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Telephonic Counselling (STC)
Number of subjects: 114
Study 22621300 — intervention group
Group type: COMPARATOR
Intervention: Conventional Counselling (C)
Number of subjects: 114
Study 19242897 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) - group therapy consisting of psychoeducation, cognitive restructuring, stress management, relaxation and mindfulness techniques.
Number of subjects: 40
Study 19242897 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - wait-list control with no intervention during the waiting period.
Number of subjects: 40
Study 19242897 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) - group therapy.
Number of subjects: 40
Study 19242897 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - wait-list control.
Number of subjects: 40
Study 18055982 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily deferiprone (DFP) 75 mg/kg plus desferrioxamine (DFO) 40-50 mg/kg twice weekly
Number of subjects: 24
Study 18055982 — intervention group
Group type: COMPARATOR
Intervention: Daily deferiprone (DFP) monotherapy
Number of subjects: 24
Study 18055982 — intervention group
Group type: COMPARATOR
Intervention: Desferrioxamine (DFO) 40-50 mg/kg 5 days weekly (reference group)
Number of subjects: 24
Study 16581423 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (Lucentis) at doses ranging from 0.3 to 2.0 mg, administered via 5, 7, or 9 intravitreal injections at 2- or 4-week intervals for 16 weeks.
Number of subjects: 32
Study 14566118 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient simulator
Number of subjects: 60
Study 14566118 — intervention group
Group type: COMPARATOR
Intervention: Moulage patient
Number of subjects: 60
Study 11556039 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen alone
Number of subjects: 88
Study 8669669 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic oxygenated blood cardioplegia (33.5 degrees C)
Number of subjects: 42
Study 8669669 — intervention group
Group type: COMPARATOR
Intervention: Hypothermic oxygenated blood cardioplegia (10 degrees C)
Number of subjects: 42
Study 1607678 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% topical minoxidil
Number of subjects: 20
Study 1607678 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle alone)
Number of subjects: 20
Study 2863148 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (15 mg intravenous followed by 200 mg daily oral for 15 days)
Number of subjects: 5778
Study 2863148 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 5778
Study 2863148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5778
Study 29956886 — intervention group
Group type: COMPARATOR
Intervention: Control VOO (80 mg kg‐1)
Number of subjects: 33
Study 29956886 — intervention group
Group type: EXPERIMENTAL
Intervention: FVOO (500 mg kg‐1)
Number of subjects: 33
Study 29956886 — intervention group
Group type: EXPERIMENTAL
Intervention: FVOOT (500 mg kg‐1; 1:1)
Number of subjects: 33
Study 27194033 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-help (6 hours of professional support)
Number of subjects: 36
Study 27194033 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized CBT (1 hour of professional support)
Number of subjects: 36
Study 24813588 — intervention group
Group type: EXPERIMENTAL
Intervention: Older infants (16-18 months)
Number of subjects: 40
Study 24813588 — intervention group
Group type: COMPARATOR
Intervention: Younger infants (12-14 months)
Number of subjects: 40
Study 22307201 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensatory oculomotor reading training
Number of subjects: 36
Study 22307201 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensatory oculomotor visual exploration training
Number of subjects: 36
Study 22307201 — intervention group
Group type: COMPARATOR
Intervention: Training sequence
Number of subjects: 36
Study 20222114 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided corticosteroid injection
Number of subjects: 184
Study 20222114 — intervention group
Group type: COMPARATOR
Intervention: CE-guided corticosteroid injection
Number of subjects: 184
Study 20222114 — intervention group
Group type: EXPERIMENTAL
Intervention: Accurate injections
Number of subjects: 184
Study 20222114 — intervention group
Group type: EXPERIMENTAL
Intervention: US guidance
Number of subjects: 184
Study 20222114 — intervention group
Group type: COMPARATOR
Intervention: CE guidance
Number of subjects: 184
Study 19100058 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin 0.075 ml/10 kg (group I, n = 120)
Number of subjects: 236
Study 19100058 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin 0.1 ml/10 kg (group II, n = 116)
Number of subjects: 236
Study 15812629 — intervention group
Group type: EXPERIMENTAL
Intervention: ITBV guided fluid therapy
Number of subjects: 40
Study 15812629 — intervention group
Group type: COMPARATOR
Intervention: CVP guided fluid therapy
Number of subjects: 40
Study 12529074 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent drinking history (RDH) measured using daily diary and timeline followback methods
Number of subjects: 110
Study 12529074 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 110
Study 10349473 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemical expression of respiratory syncytial virus
Number of subjects: 53
Study 10349473 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemical staining
Number of subjects: 53
Study 10349473 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory lesions related to RSV
Number of subjects: 53
Study 8953876 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural buprenorphine (0.2 mg) after combined spinal-epidural anesthesia (CSE group)
Number of subjects: 0
Study 8953876 — intervention group
Group type: COMPARATOR
Intervention: Epidural buprenorphine (0.2 mg) after general anesthesia combined with epidural anesthesia (EPI + GEN group)
Number of subjects: 0
Study 8953876 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CSE and EPI + GEN)
Number of subjects: 0
Study 8953876 — intervention group
Group type: EXPERIMENTAL
Intervention: CSE group
Number of subjects: 0
Study 1941406 — intervention group
Group type: EXPERIMENTAL
Intervention: SMA preterm formula containing 50% medium-chain triglycerides (MCT)
Number of subjects: 20
Study 1941406 — intervention group
Group type: EXPERIMENTAL
Intervention: SMA preterm formula containing 86% long-chain triglycerides (LCT)
Number of subjects: 20
Study 1941406 — intervention group
Group type: COMPARATOR
Intervention: S-26 full-term infant formula containing 98% LCT
Number of subjects: 20
Study 1941406 — intervention group
Group type: EXPERIMENTAL
Intervention: SMA preterm formula containing 50% MCT
Number of subjects: 20
Study 1941406 — intervention group
Group type: EXPERIMENTAL
Intervention: SMA preterm formula containing 86% LCT
Number of subjects: 20
Study 6977837 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid, 1 gm daily, and anticoagulants
Number of subjects: 142
Study 6977837 — intervention group
Group type: COMPARATOR
Intervention: No antithrombotic drugs
Number of subjects: 142
Study 30929097 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher PB CD34+ progenitor cell numbers
Number of subjects: 160
Study 30929097 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher PB CD133+ progenitor cell numbers
Number of subjects: 160
Study 30929097 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow progenitor cell numbers
Number of subjects: 160
Study 30929097 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative BM and PB progenitor cell numbers
Number of subjects: 160
Study 30929097 — intervention group
Group type: EXPERIMENTAL
Intervention: PB and BM progenitor cell numbers
Number of subjects: 160
Study 28282794 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Number of subjects: 30
Study 28282794 — intervention group
Group type: COMPARATOR
Intervention: Placebo taping
Number of subjects: 30
Study 25595470 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic treatment in acute decompensated heart failure (specific diuretic details not provided).
Number of subjects: 1088
Study 23279139 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive heart failure therapy
Number of subjects: 151
Study 23279139 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk model for predicting nonresponse
Number of subjects: 151
Study 23279139 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk model validation using BATTLESCARRED cohort
Number of subjects: 151
Study 21976561 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention not specified; control group not specified
Number of subjects: 3044
Study 21976561 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin combination treatment
Number of subjects: 3044
Study 18678461 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based education
Number of subjects: 147
Study 18678461 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face education with a nurse
Number of subjects: 147
Study 17065639 — intervention group
Group type: EXPERIMENTAL
Intervention: Resume anticoagulation
Number of subjects: 608
Study 17065639 — intervention group
Group type: COMPARATOR
Intervention: Stop anticoagulation
Number of subjects: 608
Study 17065639 — intervention group
Group type: COMPARATOR
Intervention: Normal D-dimer level
Number of subjects: 608
Study 17065639 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal D-dimer level (stop anticoagulation)
Number of subjects: 608
Study 17065639 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal D-dimer level (resume anticoagulation)
Number of subjects: 608
Study 12899797 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative chemotherapy (1-2 cycles of cisplatinum-based regimen)
Number of subjects: 211
Study 12899797 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative chemotherapy (2-4 cycles of cisplatinum-based regimen)
Number of subjects: 211
Study 12899797 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative chemotherapy (1-2 cycles) in stage II NSCLC
Number of subjects: 211
Study 12899797 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathological 'T' down stage or unchanged after pre-operative CT
Number of subjects: 211
Study 12899797 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders to pre-operative chemotherapy
Number of subjects: 211
Study 12899797 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pre-operative chemotherapy)
Number of subjects: 211
Study 11885179 — intervention group
Group type: EXPERIMENTAL
Intervention: 3+ mm diameter implants
Number of subjects: 2917
Study 11885179 — intervention group
Group type: EXPERIMENTAL
Intervention: 4+ mm diameter implants
Number of subjects: 2917
Study 11885179 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 mm length implants
Number of subjects: 2917
Study 11885179 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mm length implants
Number of subjects: 2917
Study 8614498 — intervention group
Group type: COMPARATOR
Intervention: 0.1 mmol/kg gadolinium-DTPA (standard dose)
Number of subjects: 22
Study 8614498 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mmol/kg gadolinium-DTPA (triple dose)
Number of subjects: 22
Study 1410165 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered smoking re-exposure (smoking five cigarettes)
Number of subjects: 67
Study 1410165 — intervention group
Group type: COMPARATOR
Intervention: Control group (remained abstinent)
Number of subjects: 67
Study 2856773 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 12.5 mg once daily
Number of subjects: 48
Study 2856773 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 25 mg once daily
Number of subjects: 48
Study 2856773 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 20 mg once daily
Number of subjects: 48
Study 2856773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 31397274 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) innovator product CellCept
Number of subjects: 0
Study 31397274 — intervention group
Group type: COMPARATOR
Intervention: Renodapt (generic)
Number of subjects: 0
Study 31397274 — intervention group
Group type: COMPARATOR
Intervention: Mycept (generic)
Number of subjects: 0
Study 31397274 — intervention group
Group type: COMPARATOR
Intervention: Cellmune (generic)
Number of subjects: 0
Study 27824237 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal extracorporeal shock wave therapy (f‐ESWT) plus supervised eccentric training (SET) of the shoulder abductor muscles
Number of subjects: 22
Study 27824237 — intervention group
Group type: COMPARATOR
Intervention: Focal extracorporeal shock wave therapy (f‐ESWT) only
Number of subjects: 22
Study 27619826 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First + Assertive Community Treatment (HF+ACT)
Number of subjects: 197
Study 27619826 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 197
Study 26621399 — intervention group
Group type: EXPERIMENTAL
Intervention: ONSTEP technique
Number of subjects: 188
Study 26621399 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic approach
Number of subjects: 188
Study 23486136 — intervention group
Group type: EXPERIMENTAL
Intervention: Rib plating with the Synthes Matrix Rib Plating System
Number of subjects: 117
Study 23486136 — intervention group
Group type: COMPARATOR
Intervention: No rib plating (Control)
Number of subjects: 117
Study 19010976 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal threat condition; specific details on dosage and duration not available.
Number of subjects: 0
Study 19010976 — intervention group
Group type: COMPARATOR
Intervention: Baseline condition; specific details on dosage and duration not available.
Number of subjects: 0
Study 18594042 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy
Number of subjects: 10150
Study 16845901 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 14679274 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular hyaluronic acid
Number of subjects: 22
Study 14679274 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest-molecular-weight hyaluronic acid
Number of subjects: 22
Study 11505247 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary therapies (CTs) course for nursing assistants
Number of subjects: 0
Study 9760815 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemic kidney (renal vein blood)
Number of subjects: 16
Study 9760815 — intervention group
Group type: COMPARATOR
Intervention: Normal kidney (renal vein blood)
Number of subjects: 16
Study 8156566 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth-brushing (group II)
Number of subjects: 30
Study 8156566 — intervention group
Group type: EXPERIMENTAL
Intervention: Deproteinizing (group III)
Number of subjects: 30
Study 8156566 — intervention group
Group type: COMPARATOR
Intervention: Intact surface organic material (group I)
Number of subjects: 30
Study 3048103 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine
Number of subjects: 120
Study 3048103 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 120
Study 3048103 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs together
Number of subjects: 120
Study 31901945 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient multimodal occupational rehabilitation (I‐MORE)
Number of subjects: 166
Study 31901945 — intervention group
Group type: COMPARATOR
Intervention: Outpatient acceptance and commitment therapy (O‐ACT)
Number of subjects: 166
Study 31753694 — intervention group
Group type: EXPERIMENTAL
Intervention: Savoring
Number of subjects: 468
Study 31753694 — intervention group
Group type: EXPERIMENTAL
Intervention: Rose, Thorn, Bud
Number of subjects: 468
Study 31753694 — intervention group
Group type: COMPARATOR
Intervention: Three Hard Things
Number of subjects: 468
Study 31753694 — intervention group
Group type: COMPARATOR
Intervention: Neutral control
Number of subjects: 468
Study 28533306 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine-rituximab combination therapy
Number of subjects: 45
Study 25908462 — intervention group
Group type: EXPERIMENTAL
Intervention: COSSACS - Continuation of prestroke antihypertensive therapy
Number of subjects: 942